What’s New in Acne Management: What We Have Learned from Increased Understanding of Acne Pathophysiology

Featured Article

What's New in Acne Management:

What We Have Learned From Increased Understanding of Acne Pathophysiology

Join Drs. Leon H. Kircik, Linda Stein Gold, and Jonathan S. Weiss as they discuss the medical interventions generally targeting one or more of the key factors contributing to the development of acne lesions: follicular hyperproliferation and abnormal desquamation (topical and oral retinoids, azelaic acid, salicylic acid, hormonal therapy), increase sebum production (oral isotretinoin, hormonal therapy), C. acnes proliferation (benzoyl peroxide, topical and oral antibiotics, azelaic acid) and inflammation (oral isotretinoin, oral tetracyclines, topical retinoids, azelaic acid).

Acne pathogenesis is multifactorial and not clearly understood; a key factor includes genetics and may result as in interplay of release of inflammatory mediators into the skin, follicular hyperkeratinization with subsequent plugging of the follicle, Cutibacterium acne (C. acnes), formerly Propionibacterium acnes or P. acnes, follicular colonization and excess sebum production.

C. acnes has been shown to mediate inflammatory processes at the site of the sebaceous follicle contributing to the formation of free radical species and generating pro-inflammatory cytokines. Excess sebum production and C. acnes colonization lead to the formation of microcomedones leading to the development of open or closed comedones, inflammatory papules, pustules and cysts characteristic of acne.

Acne severity and grade (comedonal, papulopustular, mixed, nodular), skin type, presence of acne scarring and postinflammatory hyperpigmentation, menstrual cycle history (in women), skin current skin care regimen are factors influencing treatment with classes of topical agents include: comedolytic (anticomedogenic), antimicrobial, antibiotic and antiinflammatory; each impact on the four main pathogenic features of acne.

FACULTY

Leon H. Kircik, MD
Clinical Professor of Dermatology
Indiana University School of Medicine
Mount Sinai Medical Center, New York, NY
Physicians Skin Care, PLLC
Louisville, KY

Linda Stein Gold, MD
Director, Dermatology Clinical Research
Henry Ford Health System
Detroit, Michigan

Jonathan S. Weiss, MD
Adjunct Assistant Clinical Professor of Dermatology
Emory University School of Medicine
Atlanta, GA
President & Co-Managing Partner
Georgia Dermatology Partners
(Formerly, Gwinnett Dermatology, PC)

Watch Now

Amelioration of Dominant Dystrophic Epidermolysis Bullosa Ulceration by Combination Gentian Violet and Trichloroacetic Acid Therapy

Mikaela Sonis | Case Reports, Featured Articles, Latest News | No Comments

Case report: six weeks of gentian violet and trichloroacetic acid peel produced marked healing in dominant dystrophic epidermolysis bullosa with minimal discomfort The February 2026 JDD issue features a case…

Journal of Drugs in Dermatology JDD Article about Combined Use of Relabotulinum Toxin A and NASHA Gel Skinbooster for Rejuvenation of the Upper Third of the Face

Combined Use of Relabotulinum Toxin A and NASHA Gel Skinbooster for Rejuvenation of the Upper Third of the Face

Mikaela Sonis | Aesthetics, Featured Articles, Latest News | No Comments

Combined Relabotulinum Toxin A frontalis modulation with NASHA™ gel skinboosters for the temples yields natural‑looking wrinkle softening and lasting skin quality gains beyond six months A preliminary clinical series tested…

Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges

Mikaela Sonis | Aesthetics, Featured Articles, Latest News | No Comments

From the Vault: Review of the last decade finds biological rationale for skin and hair benefits, yet no FDA approvals and major gaps in standardization and clinical data Dive into…

Tags:

Featured Article